Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Moreno 2013 Biomed Chromatogr

From Bioblast
Publications in the MiPMap
Moreno JM, Wojnicz A, Steegman JL, Cano-Abad MF, Ruiz-Nuño A (2013) Imatinib assay by high-performance liquid chromatography in tandem mass spectrometry with solid-phase extraction in human plasma. Biomed Chromatogr 27:502-8.

» PMID: 23034891

Moreno JM, Wojnicz A, Steegman JL, Cano-Abad MF, Ruiz-Nuno A (2013) Biomed Chromatogr

Abstract: We have developed a method of liquid chromatography in tandem with mass spectrometry to monitor therapeutic levels of imatinib in plasma, a selective inhibitor of protein tyrosine kinase. After solid-phase extraction of plasma samples, imatinib and its internal standard, imatinib-D8, were eluted with Zorbax SB-C18 at 60 °C, under isocratic conditions through a mobile phase consisting of 4 mm ammonium formate, pH: 3.2 (solution A) and acetonitrile solution B. The flow rate was 0.8 mL/min with 55% solution A + 45% solution B. Imatinib was detected and quantified by mass spectrometry with electrospray ionization operating in selected-reaction monitoring mode. The calibration curve was linear in the range 10-5000 ng/mL, the lower limit of quantitation being 10 ng/mL. The method was validated according to the recommendations of the Food and Drug Administration, including tests of matrix effect (bias < 10%) and recovery efficiency (>80 and <120%). The method is precise (coefficient of variance intra-day <2% and inter-day <7%), accurate (95-108%), sensitive and specific. It is a simple method with very fast recording time (1.2 min) that is applicable to clinical practice. This will permit improvement of the pharmacological treatment of patients.

Copyright © 2012 John Wiley & Sons, Ltd.


Labels: